Search - tctmd.com

Displaying 21 - 38 of 38

Sort: Relevancy | Date

Presentation TVT 2017

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Presenter: David J. Cohen, Mark J. Russo, Nir Uriel

June 16, 2017

Presentation TVT 2017

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Presenter: David J. Cohen, Mark J. Russo, Ran Kornowski

June 16, 2017

Presentation TVT 2017

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Presenter: David J. Cohen, Mark J. Russo, Suzanne V. Arnold

June 16, 2017

Presentation TVT 2017

Ineffective Endocarditis After TAVR: Cause for Concern?

Presenter: David J. Cohen, Mark J. Russo, Bernard Prendergast

June 16, 2017

Presentation TVT 2017

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Presenter: David J. Cohen, Mark J. Russo, Molly Szerlip

June 16, 2017

Presentation TVT 2017

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

Presenter: Ran Kornowski, Mark J. Russo, David J. Cohen

June 15, 2017

News Conference News TVT 2016

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Michael O'Riordan

June 20, 2016

Presentation TVT 2016

New TAVR Risk Models (eg, From TVT and FRANCE 2 Registries): Development, Clinical Validation, Current Use, and Future Directions

Presenter: David J. Cohen

June 17, 2016

Presentation TVT 2016

Identifying the Futile AS Patient: When Are Extreme Comorbidities Too Much for TAVR?

Presenter: David J. Cohen

June 17, 2016

Presentation TVT 2016

The Reemergence of Transcarotid TAVR as a Worthwhile Alternative

Presenter: David J. Cohen

June 16, 2016

Presentation TVT 2015

Putting It All Together: What Are the Cost Implications?

Presenter: Sandra Lauck, David A. Wood, David J. Cohen

June 06, 2015

Presentation TVT 2015

Thoughtful Commentary: AS With Extreme Comorbidities (the Futile Patient)

Presenter: Howard C. Herrmann, Alec S. Vahanian, David J. Cohen

June 04, 2015

Presentation TVT 2015

Contemporary Minimalist TAVR: More or Less Cost-Effective? What Are the Unmet Economic Needs?

Presenter: David J. Cohen

June 04, 2015

Presentation TVT 2014

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

Presenter: David J. Cohen

June 07, 2014

Presentation TVT 2013

Can We Afford TAVR? Impact on US Hospitals and Health Systems: Lessons from PARTNER and Beyond

Presenter: David Cohen

June 13, 2013

Presentation TVT 2013

TAVR Cost-effectiveness and Reimbursement: A Global Gordian Knot

Presenter: David Cohen

June 12, 2013

Presentation TVT 2012

Quality-of-Life Measures and Cost-Effectiveness After TAVR

Presenter: David Cohen

June 04, 2012

Presentation TVT 2012

Characterizing Futility from a Quality-of-Life Standpoint: Considerations Beyond Mortality

Presenter: David Cohen

June 04, 2012

Advertisement

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Ineffective Endocarditis After TAVR: Cause for Concern?

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

New TAVR Risk Models (eg, From TVT and FRANCE 2 Registries): Development, Clinical Validation, Current Use, and Future Directions

Identifying the Futile AS Patient: When Are Extreme Comorbidities Too Much for TAVR?

The Reemergence of Transcarotid TAVR as a Worthwhile Alternative

Putting It All Together: What Are the Cost Implications?

Thoughtful Commentary: AS With Extreme Comorbidities (the Futile Patient)

Contemporary Minimalist TAVR: More or Less Cost-Effective? What Are the Unmet Economic Needs?

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

Can We Afford TAVR? Impact on US Hospitals and Health Systems: Lessons from PARTNER and Beyond

TAVR Cost-effectiveness and Reimbursement: A Global Gordian Knot

Quality-of-Life Measures and Cost-Effectiveness After TAVR

Characterizing Futility from a Quality-of-Life Standpoint: Considerations Beyond Mortality

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content